AU2023221950A1 - Treatment of anatomical and functional retinal atrophies - Google Patents
Treatment of anatomical and functional retinal atrophies Download PDFInfo
- Publication number
- AU2023221950A1 AU2023221950A1 AU2023221950A AU2023221950A AU2023221950A1 AU 2023221950 A1 AU2023221950 A1 AU 2023221950A1 AU 2023221950 A AU2023221950 A AU 2023221950A AU 2023221950 A AU2023221950 A AU 2023221950A AU 2023221950 A1 AU2023221950 A1 AU 2023221950A1
- Authority
- AU
- Australia
- Prior art keywords
- eye
- condition
- retinal
- pharmaceutically acceptable
- homolog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022900318A AU2022900318A0 (en) | 2022-02-15 | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| AU2022900318 | 2022-02-15 | ||
| PCT/AU2023/050103 WO2023154980A1 (en) | 2022-02-15 | 2023-02-15 | Treatment of anatomical and functional retinal atrophies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023221950A1 true AU2023221950A1 (en) | 2024-09-19 |
Family
ID=87577221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023221950A Pending AU2023221950A1 (en) | 2022-02-15 | 2023-02-15 | Treatment of anatomical and functional retinal atrophies |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250387410A1 (https=) |
| EP (1) | EP4479061A4 (https=) |
| JP (1) | JP2025507416A (https=) |
| CN (1) | CN119031918A (https=) |
| AU (1) | AU2023221950A1 (https=) |
| WO (1) | WO2023154980A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207515B2 (en) * | 2018-01-10 | 2024-11-14 | Eye Co Pty Ltd | Medical device and pharmaceutical composition for treatment of an eye disease or condition |
| PL3684370T3 (pl) * | 2018-02-26 | 2025-07-28 | Eye Co Pty Ltd. | Kompozycja i leczenie zaniku geograficznego fludrokortyzonem |
-
2023
- 2023-02-15 US US18/837,905 patent/US20250387410A1/en active Pending
- 2023-02-15 CN CN202380025844.9A patent/CN119031918A/zh active Pending
- 2023-02-15 WO PCT/AU2023/050103 patent/WO2023154980A1/en not_active Ceased
- 2023-02-15 EP EP23755583.4A patent/EP4479061A4/en active Pending
- 2023-02-15 AU AU2023221950A patent/AU2023221950A1/en active Pending
- 2023-02-15 JP JP2024548656A patent/JP2025507416A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025507416A (ja) | 2025-03-18 |
| CN119031918A (zh) | 2024-11-26 |
| EP4479061A4 (en) | 2026-01-07 |
| WO2023154980A1 (en) | 2023-08-24 |
| US20250387410A1 (en) | 2025-12-25 |
| EP4479061A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Campochiaro et al. | Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study | |
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| Arevalo et al. | Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months | |
| Pearson et al. | Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial | |
| Wolf et al. | RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia | |
| Arevalo et al. | Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group | |
| Mayer et al. | Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome | |
| EP3886858B1 (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
| Verma et al. | A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema | |
| JP6944958B2 (ja) | 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用 | |
| CN103705524A (zh) | 具有二氟泼尼酯的黄斑水肿治疗用滴眼剂 | |
| Wang et al. | Efficacy and safety of intracameral triamcinolone acetonide to control postoperative inflammation after phacotrabeculectomy | |
| CN115697333A (zh) | 包含阿西替尼的组合物和治疗眼部疾病的方法 | |
| US20220331345A1 (en) | Methods of Treating Retinal Vasculopathies | |
| Al Zamil | Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema | |
| US20250387410A1 (en) | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| JP2018535954A (ja) | 脈絡膜血管新生の処置のための方法及び医薬組成物 | |
| Krasniqi et al. | Anti–VEGF Treatment in Macular Edema Due to Retinal Vein Occlusion | |
| Seethala et al. | Current treatments in diabetic macular edema | |
| de Zea et al. | Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy | |
| Hong et al. | Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy | |
| Matet et al. | Irvine-Gass macular edema responding to the combination of oral mineralocorticoid-receptor antagonist with dexamethasone drops | |
| Pacella | Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant: description of three case | |
| Ahmad et al. | Comparison of intravitreal Diclofenac-Sodium Versus intravitreal Triamcinolone in diabetic Macular Edema | |
| Chan et al. | Intraocular pressure changes after repeated intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration with or without glaucoma |